NCYT Insider Trading (Novacyt)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £113,219.48
Insider Selling (Last 12 Months): GBX 0
Novacyt Share Price & Price History
Current Price: GBX 163
Price Change: ▲ Price Increase of +4.4 (2.77%)
As of 06/30/2022 05:35 PM ET
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures | Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Novacyt Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/25/2022 | David Allmond | Insider | Buy | 43,500 | GBX 231 | £100,485 | | |
| 3/18/2022 | Jean-Pierre Crinelli | Insider | Buy | 3,208 | GBX 241 | £7,731.28 | | |
| 3/14/2022 | James McCarthy | Insider | Buy | 2,360 | GBX 212 | £5,003.20 | | |
| 11/10/2020 | Edwin Snape | Insider | Buy | 1,080 | GBX 715 | £7,722 | | |
| 6/3/2020 | Andrew Heath | Insider | Buy | 3,161 | GBX 305 | £9,641.05 | | |
| 5/15/2020 | James Wakefield | Insider | Buy | 20,000 | GBX 305 | £61,000 | | |
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures | Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
SEC Filings (Institutional Ownership Changes) for Novacyt (LON:NCYT)
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
Read More on Novacyt
Today's Range
Now: GBX 163
50 Day Range
MA: GBX 154.16
52 Week Range
Now: GBX 163
Volume
247,150 shs
Average Volume
379,789 shs
Market Capitalization
£115.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Novacyt?
